Bausch + Lomb Corp
NYSE:BLCO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.6
20.93
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bausch + Lomb Corp
Bausch + Lomb Corp
Cost of Revenue
Bausch + Lomb Corp
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bausch + Lomb Corp
NYSE:BLCO
|
Cost of Revenue
-$1.6B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Ostrom Climate Solutions Inc
XTSX:COO
|
Cost of Revenue
-CA$3.1m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
Bausch + Lomb Corp
Glance View
Bausch + Lomb Corp., a subsidiary of Bausch Health Companies Inc., is a global leader in the eye health sector, dedicated to enhancing the vision and overall well-being of individuals worldwide. With a history spanning over 160 years, the company has built a robust portfolio that includes contact lenses, lens care products, and surgical devices. Their commitment to innovation is evident in their continuous investment in research and development, which has led to breakthrough technologies, such as advanced ocular surgical instruments and solutions that improve the quality of life for patients with vision impairments. As the global population ages and the demand for eye care products increases, Bausch + Lomb is well-positioned to capitalize on these trends, making it an appealing consideration for investors seeking growth in a stable, essential market. In addition to its innovative product offerings, Bausch + Lomb benefits from a strong brand reputation and a well-established distribution network, allowing it to reach millions of customers across diverse markets. The company's focus on expanding its market share through strategic partnerships and acquisitions adds a layer of potential for revenue growth. Investors should note that eye health is a critical aspect of healthcare, making Bausch + Lomb's mission not only significant but also potentially lucrative. As the company navigates the evolving landscape of the health and wellness industry, its strategic focus on eye care uniquely positions it as a reliable investment opportunity for those looking to strengthen their portfolios with a company that marries tradition with modernity in a timeless sector.
See Also
What is Bausch + Lomb Corp's Cost of Revenue?
Cost of Revenue
-1.6B
USD
Based on the financial report for Dec 31, 2023, Bausch + Lomb Corp's Cost of Revenue amounts to -1.6B USD.
What is Bausch + Lomb Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-5%
Over the last year, the Cost of Revenue growth was -8%. The average annual Cost of Revenue growth rates for Bausch + Lomb Corp have been -9% over the past three years , -5% over the past five years .
You don't have any saved screeners yet
